DarioHealth Reports First Quarter 2021 Results and Operational Highlights
USA - English
Announced acquisition of Upright Technologies, expanding into the musculoskeletal and related pain conditions markets
Generated Q1 revenue growth of 73% over Q4 2020 and 116% over Q1 2020, driven by organic growth and consolidation of Upright Technologies revenues effective February 2, 2021
GAAP gross margin was 30.1% in the first quarter, excluding acquisition related amortizations Q1 2021 product gross margin nearly doubled to 44.7% as compared to 24.2% in Q4 2020
Ended the first quarter 2021 with cash and cash equivalents of $81.1 million
Company to host conference call and webcast 8:30 am ET tomorrow.
News provided by
Share this article
Share this article
DarioHealth Study Examines Connection Between Personalization and Sustained Behavior Change in Digital Health
USA - English
News provided by
Share this article
Share this article
NEW YORK, March 2, 2021 /PRNewswire/ DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, today announced the results of a new clinical study that have been published in the
Journal of Medical Internet Research (JMIR) Diabetes. The paper is titled Role of Digital Engagement in Diabetes Care Beyond Measurement: Retrospective Cohort Study.
In the world of digital health, the focus has long been the differences between people - analyzing data, patterns, and demographics to create personas that match like individuals. The idea behind many current digital health solutions is that personalization is your fingerprint , but while fingerprints don t change, people do. What an individual liked and was willing to try yesterday may not be what they are willing to